AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1657799
Drug: Intravenous enalaprilat
RxNorm normalized name: Enalaprilat
DrugBank: Enalaprilat (DB09477)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous enalaprilat (0.2-1.2 mg, mean 1.0 mg) administered as bolus to 20 patients
Trial: 1657799
Drug: Intravenous enalaprilat
RxNorm normalized name: Enalaprilat
DrugBank: Enalaprilat (DB09477)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous enalaprilat (1 mg) administered as infusion over two hours to 20 patients
Trial: 1657799
Drug: Intravenous enalaprilat
RxNorm normalized name: Enalaprilat
DrugBank: Enalaprilat (DB09477)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous enalaprilat (1 mg) administered as infusion over two hours to 8 patients with systolic blood pressure between 100-109 mmHg
Trial: 1657799
Drug: Intravenous enalaprilat
RxNorm normalized name: Enalaprilat
DrugBank: Enalaprilat (DB09477)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous enalaprilat
Trial: 1657799
Drug: Oral enalapril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral enalapril (2.5-10 mg/day) continued after intravenous treatment
Trial: 1657799
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (thrombolytic treatment, intravenous metoprolol, intravenous nitroglycerin, intravenous furosemide)
Trial: 7041943
Drug: Corynebacterium parvum
RxNorm normalized name: Corynebacterium parvum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corynebacterium parvum (CP) immunotherapy
Trial: 16083704
Drug: Rifampicin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin (600 mg/day for 1 week)
Trial: 16083704
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (1 g/day for 3 weeks)
Trial: 7577895
Drug: 60 g
RxNorm normalized name: aspirin 60 Grains
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 g textured vegetable protein (TVP)/d, containing 45 mg conjugated isoflavones
Trial: 7577895
Drug: 50 g
RxNorm normalized name: glucose 50 g/296 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 g miso/d, containing 25 mg unconjugated isoflavones
Trial: 7577895
Drug: 28 g
RxNorm normalized name: SM Syringe 28 g, 0.5cc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 28 g TVP/d, containing 23 mg conjugated isoflavones
Trial: 7577895
Drug: 60 g
RxNorm normalized name: aspirin 60 Grains
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 g of a soyabean product with chemically extracted isoflavones (Arcon F)
Trial: 7577895
Drug: 45 mg
RxNorm normalized name: lutein 45 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45 mg conjugated isoflavones as 60 g TVP
Trial: 7577895
Drug: 45 mg
RxNorm normalized name: lutein 45 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45 mg conjugated isoflavones
Trial: 7577895
Drug: 23 mg
RxNorm normalized name: morphine 0.23 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 23 mg conjugated isoflavone-free Arcon F
Trial: 31637668
Drug: Apatinib (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib (500 mg or 250 mg daily for a 4-week cycle)
Trial: 29022390
Drug: Lactobacillus reuteri
RxNorm normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus reuteri DSM 17938 (LR DSM 17938) administered for 105 days, double dosage of 4×10^8 cfu for the first 15 days, followed by standard dosage of 2×10^8 cfu
Trial: 26688435
Drug: Oil capsules
RxNorm normalized name: Castor Oil Capsules
DrugBank: Coffea arabica seed, roasted (DB15603)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oil capsules
Trial: 8557138
Drug: Danazol 600
RxNorm normalized name: Danazol
DrugBank: Danazol (DB01406)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Danazol 600 mg/d for 2 to 4 weeks (n = 15)
Trial: 8557138
Drug: Leuprolide acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide acetate depot 3.75 mg for 2 months (n = 15)
Trial: 6125562
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of antipsychotic and antidepressant medication
Trial: 30856181
Drug: Intranasal ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal ketamine and midazolam (KMIN)
Trial: 30856181
Drug: Oral ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ketamine and midazolam (KMO)
Trial: 30856181
Drug: Oral midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral midazolam (MO)
Trial: 15110095
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of PhIP (7.4 ng/g)
Trial: 15110095
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of PhIP (1.7 ng/g)
Trial: 8056578
Drug: Azelastine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azelastine (2 mg) + vitamin C (500 mg) + vitamin E (200 mg) + glutathione (200 mg)
Trial: 3202095
Drug: Combined restriction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined restriction of thiamin, riboflavin, and vitamins B-6 and C with supplementation of other vitamins at twice the RDA.
Trial: 3202095
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with supplementation of twice the RDA of all vitamins.
Trial: 31715039
Drug: Routine intravenous
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine intravenous injection procedure
Trial: 26518955
Drug: L-alanyl-glutamine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-alanyl-glutamine (50 g)
Trial: 24617168
Drug: Diclofenac 50
RxNorm normalized name: DICLOFENAC 50MG/MISOPROSTOL 200MCG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac 50 mg and placebo
Trial: 24617168
Drug: Ginger 750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginger 750 mg and placebo
Trial: 24617168
Drug: Ginger 750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginger 750 mg and Diclofenac 50 mg
Trial: 17052502
Drug: Bortezomib (Velcade)
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib (Velcade) treatment
Trial: 14727011
Drug: Continuous oral
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous oral daily ibandronate (2.5 mg/day)
Trial: 14727011
Drug: Intermittent oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent oral ibandronate (20 mg every other day for 12 doses every 3 months)
Trial: 11518354
Drug: Disodium clodronate
RxNorm normalized name: clodronate disodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disodium clodronate (300 mg to 900 mg intravenously)
Trial: 2970805
Drug: Atrial natriuretic
RxNorm normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrial natriuretic factor (ANF, 99‐126) infusion at 15 ng.kg‐1.min‐1 for 20 minutes
Trial: 30185428
Drug: Multisystemic Therapy‐Health
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multisystemic Therapy‐Health Care
Trial: 30185428
Drug: Attention control
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Attention control (weekly family supportive counseling)
Trial: 26637169
Drug: Competitive feedback
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Competitive feedback strategy (providing non-anonymous comparative feedback on appropriateness of antibiotic use)
Trial: 22968306
Drug: Protein supplementation
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein supplementation (15 g·d‐1)
Trial: 18781069
Drug: Calcium pre-rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium pre-rinse followed by a 228 microg/g F rinse
Trial: 18781069
Drug: 912 microg/g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 912 microg/g F rinse
Trial: 18781069
Drug: 228 microg/g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 228 microg/g F rinse
Trial: 17161060
Drug: s.c. beta-EPO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: s.c. beta-EPO for 3 months twice weekly, in addition to daily oral iron
Trial: 17161060
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline in s.c. injections and daily oral iron
Trial: 14616408
Drug: Voriconazole 3
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Voriconazole 3 mg kg‐1 twice daily
Trial: 14616408
Drug: Voriconazole (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voriconazole (various doses)
Trial: 9565125
Drug: Ketorolac tromethamine,
RxNorm normalized name: Ketorolac Tromethamine, 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac tromethamine, 60 mg intravenously at the time of trocar insertion
Trial: 9565125
Drug: Ibuprofen, 800
RxNorm normalized name: Ibuprofen, 800 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen, 800 mg orally an hour before surgery
Trial: 2548964
Drug: Erythromycin ethylsuccinate
RxNorm normalized name: Erythromycin Ethylsuccinate
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erythromycin ethylsuccinate (50-80 mg/kg/day in three doses during meals)
Trial: 2548964
Drug: Co-trimoxazole (6-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-trimoxazole (6-10 mg trimethoprim/kg/day in two doses after meals)
Trial: 7576
Drug: Propranolol alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol alone (80 to 160 mg)
Trial: 7576
Drug: Combined propranolol
RxNorm normalized name: propranolol and other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined propranolol (80 to 160 mg) and phenoxybenzamine (20 to 50 mg)
Trial: 7576
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy with hydrochlorothiazide (50-100 mg)
Trial: 7576
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy with hydrochlorothiazide
Trial: 21673660
Drug: Low-dose cyclophosphamide
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cyclophosphamide (CP) - oral metronomic dosing (50 mg/day)
Trial: 21673660
Drug: Low-dose cyclophosphamide
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cyclophosphamide (CP) - single intravenous dose (1,000 mg)
Trial: 21673660
Drug: Low-dose cyclophosphamide
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cyclophosphamide (CP) - both oral and intravenous
Trial: 17507163
Drug: Pregabalin 600
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pregabalin 600 mg (P600)
Trial: 12845210
Drug: Raltitrexed 3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltitrexed 3.0 mg/m² and oxaliplatin 130 mg/m² intravenously on day 1 every 3 weeks
Trial: 30132999
Drug: Neurorehabilitation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurorehabilitation therapy for 24 weeks (6 hours per week)
Trial: 30132999
Drug: Neurorehabilitation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurorehabilitation therapy
Trial: 27149033
Drug: Catheter ablation
RxNorm normalized name: CATHETER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Catheter ablation with continuation of baseline antiarrhythmic medications
Trial: 27149033
Drug: Escalated antiarrhythmic
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalated antiarrhythmic drug therapy (including amiodarone and mexiletine)
Trial: 24119840
Drug: Daily topical
RxNorm normalized name: Clindagel 1 % Once-Daily Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily topical exit-site application of antibacterial honey plus standard exit-site care
Trial: 24119840
Drug: Standard exit-site
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard exit-site care plus intranasal mupirocin prophylaxis (control group)
Trial: 21427992
Drug: safocid (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: safocid (1 g of seknidasol, 1 g of azitromycin, 150 mg of fluconasol)
Trial: 16496206
Drug: Innovative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Innovative treatment designs
Trial: 11805482
Drug: Tc-99m tetrofosmin
RxNorm normalized name: Tc-99m tetrofosmin
DrugBank: Technetium Tc-99m tetrofosmin (DB09160)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tc-99m tetrofosmin myocardial SPECT exercise and resting imaging; dosage: 370 MBq (10 mCi) during exercise, 740 MBq (20 mCi) at rest; duration: imaging performed at specified intervals after injection
Trial: 1657803
Drug: Itraconazole with
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Itraconazole with isoconazole cream
Trial: 1657803
Drug: Itraconazole with
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Itraconazole with keratolytic cream
Trial: 1657803
Drug: Itraconazole with
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Itraconazole with placebo cream
Trial: 1657803
Drug: Griseofulvin with
RxNorm normalized name: Griseofulvin
DrugBank: Griseofulvin (DB00400)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Griseofulvin with isoconazole cream
Trial: 1657803
Drug: Griseofulvin with
RxNorm normalized name: Griseofulvin
DrugBank: Griseofulvin (DB00400)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Griseofulvin with keratolytic cream
Trial: 1657803
Drug: Griseofulvin with
RxNorm normalized name: Griseofulvin
DrugBank: Griseofulvin (DB00400)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Griseofulvin with placebo cream
Trial: 6176320
Drug: Local nodal
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local nodal radiotherapy followed by chemotherapy
Trial: 6176320
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus radiotherapy to areas of bulky disease
Trial: 7881703
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg methylprednisolone tablet (Medrol)
Trial: 7881703
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg methylprednisolone intravenous formulation (Solu‐Medrol)
Trial: 2850132
Drug: Enalapril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (10 mg IV)
Trial: 2850132
Drug: Enalapril (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (30 mg day‐1 for 3 months)
Trial: 30383486
Drug: Cholecalciferol (D3)
RxNorm normalized name: CHOLECALCIFEROL (D3) 50MCG/DROP
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol (D3) 2,000 IU daily
Trial: 30383486
Drug: Cholecalciferol (D3)
RxNorm normalized name: CHOLECALCIFEROL (D3) 50MCG/DROP
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol (D3) 3,000 IU daily
Trial: 30383486
Drug: Ergocalciferol (D2)
RxNorm normalized name: ERGOCALCIFEROL (D2) 200MCG/ML ORAL DROPS
DrugBank: Ergocalciferol (DB00153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ergocalciferol (D2) 50,000 IU weekly
Trial: 30383486
Drug: Ergocalciferol (D2)
RxNorm normalized name: ERGOCALCIFEROL (D2) 200MCG/ML ORAL DROPS
DrugBank: Ergocalciferol (DB00153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ergocalciferol (D2) 50,000 IU twice weekly
Trial: 24263123
Drug: L‐NMMA in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐NMMA in healthy control subjects (CON)
Trial: 24263123
Drug: L‐NMMA in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐NMMA in patients with CHF
Trial: 8427434
Drug: Dexamethasone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (10 mg single-dose IM injection)
Trial: 8427434
Drug: Placebo (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline IM injection)
Trial: 2831320
Drug: Linoleic acid
RxNorm normalized name: Linoleic acid
DrugBank: Linoleic acid (DB14104)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linoleic acid (4 g daily safflower seed oil)
Trial: 19548448
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of Simo Decoction for STC patients in control group I (62 patients)
Trial: 19548448
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of Simo Decoction for MC patients in control group II (62 patients)
Trial: 15127082
Drug: citalopram (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: citalopram (20 mg)
Trial: 15127082
Drug: escitalopram (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: escitalopram (10 mg)
Trial: 7587035
Drug: Ceftriaxone 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 4 g once daily
Trial: 7587035
Drug: Ceftriaxone 2
RxNorm normalized name: ceftriaxone 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 2 g every 12 h
Trial: 2378239
Drug: alfentanil +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alfentanil + 67% N2O + 33% O2 + droperidol 0.015 mg/kg
Trial: 2378239
Drug: Group II
RxNorm normalized name: Platelet group IIa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group II (alfentanil + 67% N2O + 33% O2 + droperidol 0.015 mg/kg)
Trial: 489767
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg indoprofen
Trial: 17288692
Drug: Standard Current
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Current Therapy (SCT)
Trial: 15450616
Drug: Double infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Double infusion method
Trial: 9492772
Drug: Ritonavir 600
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ritonavir 600 mg twice daily (n = 543)
Trial: 8288782
Drug: Acitretin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acitretin (20 to 30 mg/day for 16 weeks)
Trial: 2205115
Drug: doxepin hydrochloride,
RxNorm normalized name: Doxepin Hydrochloride, 3 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: doxepin hydrochloride, up to 150 mg/day
Trial: 2205115
Drug: inert medication
RxNorm normalized name: inert ingredients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inert medication
Trial: 198914
Drug: Stage grouping
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stage grouping modification suggested by the Radiation Therapy Oncology Group
Trial: 21596189
Drug: Postoperative patient‐controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative patient‐controlled epidural analgesia (PCEA) with continuous infusion of ropivacaine and fentanyl (Group I)
Trial: 21596189
Drug: Postoperative patient‐controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative patient‐controlled continuous wound catheter infusion of ropivacaine (Group II)
Trial: 18823218
Drug: Posaconazole oral
RxNorm normalized name: posaconazole Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posaconazole oral suspension 200 mg 3 times/day with meals or a nutritional supplement for a minimum of 7 days to achieve steady state and for a maximum of 12 weeks.
Trial: 18823218
Drug: Posaconazole oral
RxNorm normalized name: posaconazole Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posaconazole oral suspension 200 mg 3 times/day
Trial: 11179517
Drug: tirofiban plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tirofiban plus heparin
Trial: 8275477
Drug: ICI 182780
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICI 182780 (6 mg)
Trial: 29340354
Drug: Four immediately
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four immediately loaded mini dental implants (MDIs)
Trial: 29340354
Drug: Two standard‐sized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two standard‐sized interconnected implants (STL)
Trial: 29340354
Drug: Two STL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two STL implants
Trial: 26630974
Drug: Vitamin K1
RxNorm normalized name: vitamin K1
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K1 ≥ 0.76 and 25(OH)D ≥ 50 nmol/l
Trial: 26630974
Drug: Vitamin K1
RxNorm normalized name: vitamin K1
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K1 ≥ 0.76 and 25(OH)D < 50 nmol/l
Trial: 26630974
Drug: Vitamin K1
RxNorm normalized name: vitamin K1
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K1 < 0.76 and 25(OH)D ≥ 50 nmol/l